Compare · SYK vs ZIMV
SYK vs ZIMV
Side-by-side comparison of Stryker Corporation (SYK) and ZimVie Inc. (ZIMV): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both SYK and ZIMV operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- SYK carries a market cap of $130.80B.
- Over the past year, SYK is down 12.3% and ZIMV is up 1.1% - ZIMV leads by 13.4 points.
- SYK has hit the wire 5 times in the past 4 weeks while ZIMV has been quiet.
- SYK has more recent analyst coverage (25 ratings vs 9 for ZIMV).
- Company
- Stryker Corporation
- ZimVie Inc.
- Price
- $334.59-1.92%
- $18.99+0.00%
- Market cap
- $130.80B
- -
- 1M return
- +2.94%
- +0.37%
- 1Y return
- -12.32%
- +1.12%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 5
- 0
- Recent ratings
- 25
- 9
Stryker Corporation
Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical device products that are used in various medical specialties. The Neurotechnology and Spine segment provides neurotechnology products, which include products used for minimally invasive endovascular techniques; products for brain and open skull based surgical procedures; orthobiologic and biosurgery products, such as synthetic bone grafts and vertebral augmentation products; and minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke. This segment also offers spinal implant products comprising cervical, thoracolumbar, and interbody systems that are used in spinal injury, deformity, and degenerative therapies. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 75 countries. Stryker Corporation was founded in 1941 and is headquartered in Kalamazoo, Michigan.
ZimVie Inc.
ZimVie Inc., a medical technology company, develops, manufactures, and delivers a portfolio of products and solutions designed to treat a range of spine pathologies, and support dental tooth replacement and restoration procedures worldwide. It offers dental implant systems, prosthetic and abutment products, surgical instrumentation, and kits; bone grafts, barrier membranes, allografts, and collagen wound care products; intraoral scanners; and virtual treatment planning services, guided surgery solutions, CAD/CAM workflow systems, and patient-specific restorative components and intra-oral scanners, as well as spinal fusion implants and instrumentation for various spinal procedures, biologics, and bone healing technologies. The company also provides MIS solutions, such as Vital MIS and Timberline; and motion preservation solutions, including Mobi-C and The Tether. ZimVie Inc. was incorporated in 2021 and is headquartered in Westminster, Colorado.
Latest SYK
- SEC Form 10-Q filed by Stryker Corporation
- Stryker Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Stryker reports second quarter 2026 operating results
- UBS resumed coverage on Stryker with a new price target
- Stryker expands Mako robotics portfolio with full market release of Mako RPS
- BMO Capital Markets initiated coverage on Stryker with a new price target
- Stryker to announce second quarter 2026 financial results
- Stryker Corporation filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Stryker partners with professional golfer Shane Lowry to spotlight the caregiver journey in joint replacement
- Fresh Off Its Nasdaq Debut, a Regenerative-Medicine Upstart Is Stacking Its Board With Big-Pharma Firepower
Latest ZIMV
- Amendment: SEC Form SCHEDULE 13G/A filed by ZimVie Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by ZimVie Inc.
- SEC Form 15-12G filed by ZimVie Inc.
- Amendment: SEC Form SCHEDULE 13D/A filed by ZimVie Inc.
- Amendment: SEC Form 25-NSE/A filed by ZimVie Inc.
- Officer Kanaglekar Indraneel returned 63,438 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Director Crawford Sally returned 40,127 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Officer Schneider Sandra returned 40,794 shares to the company, closing all direct ownership in the company (SEC Form 4)
- SEC Form 4 filed by Director Asar Vinit K
- Officer Kidwell Heather returned 83,674 shares to the company, closing all direct ownership in the company (SEC Form 4)